Vladimir P Torchilin

List of Publications by Year
in descending order

134 papers	22,845 citations	28190 55 h-index	15218 126 g-index
141 all docs	141 docs citations	141 times ranked	26015 citing authors

#	Article	IF	Citations
1	Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 2005, 4, 145-160.	21.5	4,338
2	Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 2011, 63, 131-135.	6.6	1,741
3	Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 2014, 13, 813-827.	21.5	1,244
4	New Developments in Liposomal Drug Delivery. Chemical Reviews, 2015, 115, 10938-10966.	23.0	1,183
5	Multifunctional nanocarriersâ˜†. Advanced Drug Delivery Reviews, 2006, 58, 1532-1555.	6.6	1,124
6	Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS Journal, 2007, 9, E128-E147.	2.2	657
7	Cell-penetrating peptides: breaking through to the other side. Trends in Molecular Medicine, 2012, 18, 385-393.	3.5	586
8	Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 431-444.	2.0	524
9	Current trends in the use of liposomes for tumor targeting. Nanomedicine, 2013, 8, 1509-1528.	1.7	514
10	Matrix Metalloprotease 2-Responsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting. ACS Nano, 2012, 6, 3491-3498.	7.3	453
11	Hydrogels and Their Applications in Targeted Drug Delivery. Molecules, 2019, 24, 603.	1.7	439
12	Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochimica Et Biophysica Acta - Biomembranes, 1991, 1062, 142-148.	1.4	433
13	Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example. Handbook of Experimental Pharmacology, 2010, , 3-53.	0.9	427
14	Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1972-1977.	3.3	421
15	Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Advanced Drug Delivery Reviews, 2008, 60, 548-558.	6.6	402
16	Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Letters, 1991, 284, 263-266.	1.3	351
17	Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives. ACS Nano, 2018, 12, 10636-10664.	7.3	320
18	Recent advancements in liposome technology. Advanced Drug Delivery Reviews, 2020, 156, 4-22.	6.6	301

#	Article	IF	Citations
19	Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. International Journal of Pharmaceutics, 2002, 240, 95-102.	2.6	299
20	Stimuli-sensitive nanopreparations for combination cancer therapy. Journal of Controlled Release, 2014, 190, 352-370.	4.8	299
21	Nanopreparations to overcome multidrug resistance in cancer. Advanced Drug Delivery Reviews, 2013, 65, 1748-1762.	6.6	294
22	Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Research, 2002, 62, 6831-6.	0.4	278
23	Cell penetrating peptideâ€modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers, 2008, 90, 604-610.	1.2	247
24	Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. Journal of Controlled Release, 2012, 159, 393-402.	4.8	239
25	Nanopreparations for organelle-specific delivery in cancer. Advanced Drug Delivery Reviews, 2014, 66, 26-41.	6.6	237
26	Barriers to drug delivery in solid tumors. Tissue Barriers, 2014, 2, e29528.	1.6	236
27	Stimulus-responsive nanopreparations for tumor targeting. Integrative Biology (United Kingdom), 2013, 5, 96-107.	0.6	213
28	Liposomes as â€˜smartâ€™ pharmaceutical nanocarriers. Soft Matter, 2010, 6, 4026.	1.2	212
29	Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. Journal of Controlled Release, 2018, 277, 89-101.	4.8	212
30	Applications of polymer micelles for imaging and drug delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2015, 7, 691-707.	3.3	198
31	Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials, 2014, 35, 4213-4222.	5.7	195
32	Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting. Journal of Drug Delivery, 2013, 2013, 1-32.	2.5	183
33	Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy <i>In vivo</i> of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody. Clinical Cancer Research, 2009, 15, 1973-1980.	3.2	159
34	Enhanced transfection of tumor cellsin vivousing â€œSmartâ€•pH-sensitive TAT-modified pegylated liposomes. Journal of Drug Targeting, 2007, 15, 538-545.	2.1	158
35	On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles. Nature Medicine, 2014, 20, 778-784.	15.2	146
36	Intracellular delivery of protein and peptide therapeutics. Drug Discovery Today: Technologies, 2008, 5, e95-e103.	4.0	143

#	Article	IF	Citations
37	The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 539-550.	2.0	138
38	Antibody-modified liposomes for cancer chemotherapy. Expert Opinion on Drug Delivery, 2008, 5, 1003-1025.	2.4	135
39	Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. International Journal of Pharmaceutics, 2014, 464, 178-184.	2.6	108
40	Intracellular delivery of nanocarriers and targeting to subcellular organelles. Expert Opinion on Drug Delivery, 2016, 13, 49-70.	2.4	99
41	Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 105, 40-49.	2.0	95
42	Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin. Drug Delivery, 2019, 26, 765-772.	2.5	92
43	Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 54-67.	2.0	89
44	Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials, 2018, 170, 26-36.	5.7	88
45	Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer. Journal of Controlled Release, 2021, 330, 1220-1228.	4.8	85
46	Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Delivery, 2018, 25, 517-532.	2.5	84
47	Gellan gum nanohydrogel containing anti-inflammatory and anti-cancer drugs: a multi-drug delivery system for a combination therapy in cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 208-216.	2.0	83
48	Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 18-28.	2.0	81
49	Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNAâ€34a Coâ€Delivery Triggered by Dual Stimuli in Tumor Tissue. Small, 2016, 12, 4837-4848.	5.2	79
50	Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine, 2010, 5, 563-574.	1.7	78
51	Multifunctional Polymeric Micelles Co-loaded with Antiâ€"Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer. Molecular Cancer Therapeutics, 2015, 14, 1075-1084.	1.9	78
52	Enhanced tumor MR imaging with gadoliniumâ€loaded polychelating polymerâ€containing tumorâ€targeted liposomes. Journal of Magnetic Resonance Imaging, 2008, 27, 574-580.	1.9	71
53	Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting. Journal of Drug Targeting, 2011, 19, 552-561.	2.1	67
54	Cationic Liposomes Loaded with Proapoptotic Peptide <scp>d</scp>-(KLAKLAK)₂ and Bcl-2 Antisense Oligodeoxynucleotide G3139 for Enhanced Anticancer Therapy. Molecular Pharmaceutics, 2009, 6, 971-977.	2.3	64

#	Article	IF	Citations
55	Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors. Gene Therapy, 2015, 22, 257-266.	2.3	61
56	Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Molecular Cancer Therapeutics, 2016, 15, 2282-2293.	1.9	57
57	Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models. Cancer Biology and Therapy, 2014, 15, 69-80.	1.5	54
58	Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. Journal of Controlled Release, 2015, 219, 269-277.	4.8	54
59	Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: <i>In Vitro</i> Evaluation on HeLa, A2780-ADR, and H69-AR Cells. Molecular Pharmaceutics, 2016, 13, 428-437.	2.3	51
60	Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 421-430.	1.7	50
61	Development of the Novel PEG-PE-Based Polymer for the Reversible Attachment of Specific Ligands to Liposomes: Synthesis and in Vitro Characterization. Bioconjugate Chemistry, 2011, 22, 2005-2013.	1.8	47
62	Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Letters, 2013, 334, 293-301.	3.2	46
63	The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. Journal of Drug Targeting, 2008, 16, 596-600.	2.1	45
64	The effect of low- and high-penetration light on localized cancer therapy. Advanced Drug Delivery Reviews, 2019, 138, 105-116.	6.6	44
65	Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment. Cancer Biology and Therapy, 2016, 17, 698-707.	1.5	43
66	Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors. Journal of Pharmaceutical Investigation, 2017, 47, 37-49.	2.7	43
67	Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. International Journal of Pharmaceutics, 2020, 590, 119915.	2.6	43
68	<scp>d</scp>-Î±-Tocopheryl Succinate/Phosphatidyl Ethanolamine Conjugated Amphiphilic Polymer-Based Nanomicellar System for the Efficient Delivery of Curcumin and To Overcome Multiple Drug Resistance in Cancer. ACS Applied Materials & Interfaces, 2017, 9, 16778-16792.	4.0	41
69	The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles. Journal of Drug Targeting, 2017, 25, 225-234.	2.1	41
70	Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers. Drug Delivery, 2019, 26, 443-458.	2.5	40
71	Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 321-326.	2.0	39
72	Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy. PLoS ONE, 2015, 10, e0128910.	1.1	38

#	Article	IF	Citations
73	Nanosized cancer cell-targeted polymeric immunomicelles loaded with superparamagnetic iron oxide nanoparticles. Journal of Nanoparticle Research, 2009, 11, 1777-1785.	0.8	37
74	Phospholipid-modified polyethylenimine-based nanopreparations for siRNAâ€“mediated gene silencing: Implications for transfection and the role of lipid components. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 411-419.	1.7	37
75	PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity. Acta Biomaterialia, 2017, 55, 443-454.	4.1	35
76	Paclitaxel-Loaded PEG-PEâ€“Based Micellar Nanopreparations Targeted with Tumor-Specific Landscape Phage Fusion Protein Enhance Apoptosis and Efficiently Reduce Tumors. Molecular Cancer Therapeutics, 2014, 13, 2864-2875.	1.9	31
77	Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins. International Journal of Hyperthermia, 2018, 34, 934-942.	1.1	31
78	Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 43-49.	2.0	31
79	Therapeutic delivery using cell-penetrating peptides. European Journal of Nanomedicine, 2013, 5, .	0.6	28
80	Elucidating the role of free polycations in gene knockdown by siRNA polyplexes. Acta Biomaterialia, 2016, 35, 248-259.	4.1	28
81	Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA. Molecular Pharmaceutics, 2020, 17, 1638-1647.	2.3	28
82	Multifunctional Liposomes. Methods in Molecular Biology, 2017, 1530, 41-61.	0.4	27
83	Nanodrug-Enhanced Radiofrequency Tumor Ablation: Effect of Micellar or Liposomal Carrier on Drug Delivery and Treatment Efficacy. PLoS ONE, 2014, 9, e102727.	1.1	27
84	Folate targeted lipid chitosan hybrid nanoparticles for enhanced anti-tumor efficacy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102228.	1.7	26
85	â€œSmartâ€•self-assembled structures: toward intelligent dual responsive drug delivery systems. Biomaterials Science, 2020, 8, 5787-5803.	2.6	25
86	Cytotoxicity of Novel Redox Sensitive PEG2000-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells. Pharmaceutical Research, 2020, 37, 65.	1.7	25
87	<i>In vitro</i>optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein. Journal of Drug Targeting, 2011, 19, 597-605.	2.1	24
88	A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells. Cancers, 2019, 11, 1982.	1.7	23
89	Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. Journal of Controlled Release, 2015, 220, 160-168.	4.8	22
90	Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey. Current Pharmaceutical Biotechnology, 2016, 17, 728-740.	0.9	22

#	Article	IF	Citations
91	Library of Cationic Polymers Composed of Polyamines and Arginine as Gene Transfection Agents. ACS Omega, 2019, 4, 2090-2101.	1.6	22
92	The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: implications for targeting tumour-initiating cells. Journal of Drug Targeting, 2019, 27, 601-613.	2.1	22
93	Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy. Biomedical Microdevices, 2018, 20, 59.	1.4	21
94	Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy. Pharmaceutical Research, 2021, 38, 429-450.	1.7	21
95	Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases. Molecules, 2021, 26, 3304.	1.7	21
96	Hypoxia-Responsive Copolymer for siRNA Delivery. Methods in Molecular Biology, 2016, 1372, 139-162.	0.4	20
97	Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating. International Journal of Pharmaceutics, 2015, 495, 186-193.	2.6	19
98	Radiofrequency Ablationâ€"Induced Upregulation of Hypoxia-Inducible Factor-1Î± Can Be Suppressed with Adjuvant Bortezomib or Liposomal Chemotherapy. Journal of Vascular and Interventional Radiology, 2014, 25, 1972-1982.	0.2	18
99	Transferrin/Î±-tocopherol modified poly(amidoamine) dendrimers for improved tumor targeting and anticancer activity of paclitaxel. Nanomedicine, 2019, 14, 3159-3176.	1.7	18
100	Lipid-Based Drug Delivery Systems in Regenerative Medicine. Materials, 2021, 14, 5371.	1.3	16
101	Improving Peptide Applications Using Nanotechnology. Current Topics in Medicinal Chemistry, 2015, 16, 253-270.	1.0	16
102	Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents. Therapeutic Delivery, 2010, 1, 257-272.	1.2	15
103	Next step in drug delivery: getting to individual organelles. Drug Delivery and Translational Research, 2012, 2, 415-417.	3.0	15
104	Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model. Pharmaceutical Research, 2016, 33, 2540-2551.	1.7	15
105	The Cytotoxic Action of Cytochrome C/Cardiolipin Nanocomplex (Cyt-CL) on Cancer Cells in Culture. Pharmaceutical Research, 2017, 34, 1264-1275.	1.7	15
106	Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. International Journal of Pharmaceutics, 2017, 532, 149-156.	2.6	15
107	In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes. International Journal of Nanomedicine, 2014, 9, 963.	3.3	14
108	Combination Nanopreparations of a Novel Proapoptotic Drug â€" NCL-240, TRAIL and siRNA. Pharmaceutical Research, 2016, 33, 1587-1601.	1.7	13

#	Article	IF	Citations
109	Targeted Drug Delivery Systems: Strategies and Challenges. Advances in Delivery Science and Technology, 2015, , 3-38.	0.4	11
110	Hypoxia-sensitive drug delivery to tumors. Journal of Controlled Release, 2022, 341, 431-442.	4.8	11
111	Tumor-Targeted Immuno-liposomes for Delivery of Chemotherapeutics and Diagnostics. Journal of Pharmaceutical Innovation, 2008, 3, 51-58.	1.1	10
112	Liquid crystalline nanodispersion functionalized with cell-penetrating peptides improves skin penetration and anti-inflammatory effect of lipoic acid after in vivo skin exposure to UVB radiation. Drug Delivery and Translational Research, 2020, 10, 1810-1828.	3.0	10
113	Optimization of Landscape Phage Fusion Protein-Modified Polymeric Peg-Pe Micelles for Improved Breast Cancer Cell Targeting. Journal of Nanomedicine & Nanotechnology, 2011, s4, 008.	1.1	10
114	Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect. ACS Applied Materials & Interfaces, 2022, 14, 28439-28454.	4.0	10
115	Optimizing liposomes for delivery of Bowman-Birk protease inhibitors â€" Platforms for multiple biomedical applications. Colloids and Surfaces B: Biointerfaces, 2018, 167, 474-482.	2.5	9
116	Gadolinium-loaded polychelating amphiphilic polymer as an enhanced MRI contrast agent for human multiple myeloma and non Hodgkin's lymphoma (human Burkitt's lymphoma). RSC Advances, 2014, 4, 18007.	1.7	7
117	Effect of thermal dose on heat shock protein expression after radio-frequency ablation with and without adjuvant nanoparticle chemotherapies. International Journal of Hyperthermia, 2016, 32, 829-841.	1.1	7
118	Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer. Journal of Drug Targeting, 2018, 26, 505-515.	2.1	7
119	Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors. Advances in Delivery Science and Technology, 2014, , 3-45.	0.4	7
120	Gadolinium-Loaded Polychelating Polymer-Containing Tumor-Targeted Liposomes. Methods in Molecular Biology, 2017, 1522, 179-192.	0.4	6
121	Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps. MAbs, 2020, 12, 1850394.	2.6	6
122	Stimuli-responsive polymeric micelles for extracellular and intracellular drug delivery. , 2019, , 269-304.		5
123	MANÎ±1â€2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHVâ€1. Transboundary and Emerging Diseases, 2021, 68, 587-597.	1.3	4
124	Characterization of a Nanovaccine Platform Based on an Î±1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells. Molecular Pharmaceutics, 2021, 18, 2540-2555.	2.3	3
125	Targeted siRNA nanotherapeutics against breast and ovarian metastatic cancer: a comprehensive review of the literature. Nanomedicine, 2022, 17, 41-64.	1.7	2
126	Synthesis of Doxorubicin and miRNA Stimuli-Sensitive Conjugates for Combination Therapy. Methods in Molecular Biology, 2019, 1974, 99-109.	0.4	1

#	Article	IF	Citations
127	Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts. , 2013, 6, 425.		1
128	Many faces of nanomedicine. Drug Delivery and Translational Research, 2013, 3, 382-383.	3.0	0
129	Targeted imaging. Advanced Drug Delivery Reviews, 2014, 76, 1.	6.6	0
130	NANOTHERANOSTICS IN GENE THERAPY. , 2016, , 191-221.		0
131	Stimuli-Sensitive Nanopreparations: Overview. , 2016, , 1-48.		0
132	Modification of Nanoparticles with Transferrin for Targeting Brain Tissues. Methods in Molecular Biology, 2021, 2355, 49-56.	0.4	0
133	Liposomal Membrane Modification, Polymers for. , 0, , 4348-4368.		0
134	SOLID LIPID NANOPARTICLES AND NANOSTRUCTURED LIPID CARRIERS AS ANTI-CANCER DELIVERY SYSTEMS FOR THERAPY AND DIAGNOSTICS. Frontiers in Nanobiomedical Research, 2018, , 317-344.	0.1	0